Radioembolization with yttrium-90 microspheres for pancreatic cancer liver metastases: results from a pilot study

被引:22
作者
Cao, Christopher [2 ]
Yan, Tristan D. [2 ]
Morris, David L. [2 ]
Bester, Lourens [1 ]
机构
[1] Univ New S Wales, St Vincents Hosp, Dept Intervent Radiol, Sydney, NSW 2000, Australia
[2] Univ New S Wales, St George Hosp, Dept Surg, Sydney, NSW 2000, Australia
来源
TUMORI JOURNAL | 2010年 / 96卷 / 06期
关键词
liver metastasis; microspheres; pancreatic carcinoma; radioembolization; yttrium-90; ART BRACHYTHERAPY TREATMENT; GEMCITABINE; MALIGNANCIES; CARCINOMA; RESECTION;
D O I
10.1177/548.6515
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Patients with liver metastases from pancreatic adenocarcinomas have a dismal prognosis. Surgical resection remains the only curative option but is appropriate for only a minority of patients as a treatment option. This is the first study to examine the safety and efficacy of radioembolization with yttirum-90 microspheres for these patients. Patients and methods. All patients with histologically proven pancreatic carcinoma liver metastases referred to a single institution from 2006-2009 were included in the study. After radioembolization, follow-up abdominal computed tomography scans were performed to assess response according to the Response Criteria in Solid Tumors guidelines. Results. Seven patients were identified from our prospectively collected data base. Of the five patients with available computed tomography follow-up, 2 patients achieved a partial response and 1 patient had stable disease. One patient with partial response survived for nearly 15 months after radioembolization therapy. No patient experienced major post-radioembolization complications. Conclusions. Radioembolization with yttrium-90 microspheres may have a useful role in treating patients with pancreatic carcinoma liver metastases in a multimodality setting. Results of the current study warrant further investigation of this novel treatment. Free full text available at www.tumorionline.it
引用
收藏
页码:955 / 958
页数:4
相关论文
共 18 条
[1]  
ANDREWS JC, 1994, J NUCL MED, V35, P1637
[3]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[4]   Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases [J].
Cao, C. Q. ;
Yan, T. D. ;
Bester, L. ;
Liauw, W. ;
Morris, D. L. .
BRITISH JOURNAL OF SURGERY, 2010, 97 (04) :537-543
[5]   Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer [J].
Cunningham, David ;
Chau, Ian ;
Stocken, Deborah D. ;
Valle, Juan W. ;
Smith, David ;
Steward, William ;
Harper, Peter G. ;
Dunn, Janet ;
Tudur-Smith, Catrin ;
West, Julia ;
Falk, Stephen ;
Crellin, Adrian ;
Adab, Fawzi ;
Thompson, Joyce ;
Leonard, Pauline ;
Ostrowski, Joe ;
Eatock, Martin ;
Scheithauer, Werner ;
Herrmann, Richard ;
Neoptolemos, John P. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5513-5518
[6]   Fixed-Dose-Rate Gemcitabine in Combination with Oxaliplatin in Patients with Metastatic Pancreatic Cancer Refractory to Standard-Dose-Rate Gemcitabine: A Single-Institute Study [J].
Fortune, Brett E. ;
Li, Xiaobai ;
Kosuri, Kavitha V. ;
Weatherby, Lynn M. ;
Thomas, James P. ;
Bekaii-Saab, Tanios S. .
ONCOLOGY, 2009, 76 (05) :333-337
[7]  
GRIFFIN JF, 1990, CANCER, V66, P56, DOI 10.1002/1097-0142(19900701)66:1<56::AID-CNCR2820660112>3.0.CO
[8]  
2-6
[9]   HEPATIC MALIGNANCIES - IMPROVED TREATMENT WITH INTRAARTERIAL Y-90 [J].
HERBA, MJ ;
ILLESCAS, FF ;
THIRLWELL, MP ;
BOOS, GJ ;
ROSENTHALL, L ;
ATRI, M ;
BRET, PM .
RADIOLOGY, 1988, 169 (02) :311-314
[10]   Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres [J].
K. Katsumata ;
H. Tomioka ;
T. Sumi ;
T. Yamasaki ;
M. Takagi ;
F. Kato ;
Y. Suzuki ;
T. Aoki ;
Y. Koyanagi .
International Journal of Clinical Oncology, 2003, 8 (2) :110-112